COMIRNATY COVID-19 VACCIN medication leaflet 30mcg/dose x195 CONCENTRATE FOR INJECTION DISPERSION BIONT

Comirnaty is a vaccine used for preventing COVID-19 caused by SARS-CoV-2 virus.

Comirnaty 30 micrograms/dose concentrate for dispersion for injection is given to adults and adolescents from 12 years of age and older.

The vaccine causes the immune system (the body’s natural defences) to produce antibodies and blood cells that work against the virus, so giving protection against COVID-19.

As Comirnaty does not contain the virus to produce immunity, it cannot give you COVID-19.

Comirnaty should not be given

• if you are allergic to the active substance or any of the other ingredients of this medicine (listed in section 6)

Talk to your doctor, pharmacist or nurse before you are given the vaccine if:

• you have ever had a severe allergic reaction or breathing problems after any other vaccine injection or after you were given Comirnaty in the past.

• you are feeling nervous about the vaccination process or have ever fainted following any needle injection.

• you have a severe illness or infection with high fever. However, you can have your vaccination if you have a mild fever or upper airway infection like a cold.

• you have a bleeding problem, you bruise easily or you use a medicine to prevent blood-clots.

• you have a weakened immune system, because of a disease such as HIV infection or a medicine such as corticosteroid that affects your immune system.

There is an increased risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) after vaccination with Comirnaty (see section 4). These conditions can develop within just a few days after vaccination and have primarily occurred within

14 days. They have been observed more often after the second vaccination, and more often in younger males. Following vaccination, you should be alert to signs of myocarditis and pericarditis, such as breathlessness, palpitations and chest pain, and seek immediate medical attention should these occur.

As with any vaccine, Comirnaty may not fully protect all those who receive it and it is not known how long you will be protected.

You may receive a third dose of Comirnaty. The efficacy of Comirnaty, even after a third dose, may be lower in people who are immunocompromised. In these cases, you should continue to maintain physical precautions to help prevent COVID-19. In addition, your close contacts should be vaccinated as appropriate. Discuss appropriate individual recommendations with your doctor.

Comirnaty 30 micrograms/dose concentrate for dispersion for injection is not recommended for children aged under 12 years.

There is a paediatric presentation available for children 5 to 11 years of age. For details, please refer to the Package Leaflet for Comirnaty 10 micrograms/dose concentrate for dispersion for injection.

Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines or have recently received any other vaccine.

If you are pregnant or think you may be pregnant, tell your doctor, nurse or pharmacist before you receive this vaccine.

Comirnaty can be used during pregnancy. A large amount of information from pregnant women vaccinated with Comirnaty during the second and third trimester have not shown negative effects on the pregnancy or the newborn baby. While information on effects on pregnancy or the newborn baby after vaccination during the first trimester is limited, no change to the risk for miscarriage has been seen.

Comirnaty can be given during breast-feeding.

Some of the effects of vaccination mentioned in section 4 (Possible side effects) may temporarily affect your ability to drive or use machines. Wait until these effects have worn off before you drive or use machines.

Comirnaty contains potassium and sodium

This vaccine contains less than 1 mmol potassium (39 mg) per dose, that is to say essentially

‘potassium-free’.

This vaccine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially

‘sodium-free’.

Comirnaty is given after dilution as an injection of 0.3 mL into a muscle of your upper arm.

You will receive 2 injections.

It is recommended to receive the second dose of the same vaccine 3 weeks after the first dose to complete the vaccination course.

If you are immunocompromised, you may receive a third dose of Comirnaty at least 28 days after the second dose.

A booster dose of Comirnaty should be given as early as 3 months after the primary vaccination course with Comirnaty in individuals 12 years of age and older.

Comirnaty may also be given as a booster dose to individuals 18 years of age and older who have received a primary vaccination course comprised of another mRNA vaccine or adenoviral vector vaccine. Please check with your healthcare provider regarding eligibility for and timing of the booster dose.

If you have any further questions on the use of Comirnaty, ask your doctor, pharmacist or nurse.

Like all vaccines, Comirnaty can cause side effects, although not everybody gets them.

Very common side effects: may affect more than 1 in 10 people

• injection site: pain, swelling

• tiredness

• headache

• muscle pain

• chills

• joint pain

• diarrhoea

• fever

Some of these side effects were slightly more frequent in adolescents 12 to 15 years than in adults.

Common side effects: may affect up to 1 in 10 people

• injection site redness

• nausea

• vomiting

Uncommon side effects: may affect up to 1 in 100 people

• enlarged lymph nodes (more frequently observed after the booster dose)

• feeling unwell

• arm pain

• insomnia

• injection site itching

• allergic reactions such as rash or itching

• feeling weak or lack of energy/sleepy

• decreased appetite

• excessive sweating

• night sweats

Rare side effects: may affect up to 1 in 1,000 people

• temporary one sided facial drooping

• allergic reactions such as hives or swelling of the face

Very rare side effects: may affect up to 1 in 10,000 people

• inflammation of the heart muscle (myocarditis) or inflammation of the lining outside the heart (pericarditis) which can result in breathlessness, palpitations or chest pain

Not known (cannot be estimated from the available data)

• severe allergic reaction

• extensive swelling of the vaccinated limb

• swelling of the face (swelling of the face may occur in patients who have had facial dermatological fillers)

• a skin reaction that causes red spots or patches on the skin, that may look like a target or

“bulls-eye” with a dark red centre surrounded by paler red rings (erythema multiforme)

• unusual feeling in the skin, such as tingling or a crawling feeling (paraesthesia)

• decreased feeling or sensitivity, especially in the skin (hypoaesthesia)

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V and include batch/Lot number if available. By reporting side effects you can help provide more information on the safety of this medicine.

Keep this medicine out of the sight and reach of children.

The following information about storage, expiry and use and handling is intended for healthcare professionals.

Store in freezer at -90 °C to -60 °C. Unopened vials may be stored and transported at -25 °C to -15 °C for a single period of up to 2 weeks and can be returned to -90 °C to -60 °C; not exceeding the printed expiry date (EXP).

Store in the original package in order to protect from light.

When stored frozen at -90 °C to -60 °C, 195-vial packs of the vaccine can be thawed at 2 °C to 8 °C for 3 hours or individual vials can be thawed at room temperature (up to 30 °C) for 30 minutes.

Transfers of frozen vials stored at ultra-low temperature (< -60 °C)

• Closed-lid vial trays containing 195 vials removed from ultra-low temperature frozen storage (< -60 °C) may be at temperatures up to 25 °C for up to 5 minutes.

• Open-lid vial trays, or vial trays containing less than 195 vials, removed from ultra-low temperature frozen storage (< -60 °C) may be at temperatures up to 25 °C for up to 3 minutes.

• After vial trays are returned to frozen storage following temperature exposure up to 25 °C, they must remain in frozen storage for at least 2 hours before they can be removed again.

Transfers of frozen vials stored at -25 °C to -15 °C

• Closed-lid vial trays containing 195 vials removed from frozen storage (-25 °C to -15 °C) may be at temperatures up to 25 °C for up to 3 minutes.

• Open-lid vial trays, or vial trays containing less than 195 vials, removed from frozen storage (-25 °C to -15 °C) may be at temperatures up to 25 °C for up to 1 minute.

Once a vial is removed from the vial tray, it should be thawed for use.

After thawing, the vaccine should be diluted and used immediately. However, in-use stability data have demonstrated that once removed from freezer, the undiluted vaccine can be stored for up to

1 month at 2 °C to 8 °C; not exceeding the printed expiry date (EXP). Within the 1-month shelf life at

2 °C to 8 °C, up to 12 hours may be used for transportation. Prior to use, the unopened vaccine can be stored for up to 2 hours at temperatures up to 30 °C.

Thawed vials can be handled in room light conditions.

After dilution, store and transport the vaccine at 2 °C to 30 °C and use within 6 hours. Discard any unused vaccine.

Once removed from the freezer and diluted, the vials should be marked with the new discard date and time. Once thawed, the vaccine cannot be re-frozen.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

• The active substance is COVID-19 mRNA Vaccine called tozinameran. After dilution, the vial contains 6 doses of 0.3 mL with 30 micrograms tozinameran each.

• The other ingredients are:

− ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315)

− 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159)

− 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC)

− cholesterol

− potassium chloride

− potassium dihydrogen phosphate

− sodium chloride

− disodium phosphate dihydrate

− sucrose

− water for injections

− sodium hydroxide (for pH adjustment)

− hydrochloric acid (for pH adjustment)

The vaccine is a white to off-white dispersion (pH: 6.9 - 7.9) provided in a multidose vial of 6 doses in a 2 mL clear vial (type I glass), with a rubber stopper and a purple flip-off plastic cap with aluminium seal.

Pack size: 195 vials

BioNTech Manufacturing GmbH

An der Goldgrube 12

55131 Mainz

Germany

Phone: +49 6131 9084-0

Fax: +49 6131 9084-2121 service@biontech.de

BioNTech Manufacturing GmbH

Kupferbergterrasse 17 - 19

55116 Mainz

Germany

Pfizer Manufacturing Belgium NV

Rijksweg 12

2870 Puurs

Belgium

Authorisation Holder:

België/Belgique/Belgien Lietuva

Luxembourg/Luxemburg Pfizer Luxembourg SARL filialas Lietuvoje

Pfizer S.A./N.V. Tel. +370 52 51 4000

Tél/Tel: +32 (0)2 554 62 11

България Magyarország

Пфайзер Люксембург САРЛ, Клон Pfizer Kft

България Tel: +36 1 488 3700

Teл: +359 2 970 4333

Česká republika Malta

Pfizer, spol. s r.o. Vivian Corporation Ltd.

Tel: +420 283 004 111 Tel: +35621 344610

Danmark Norge

Pfizer ApS Pfizer AS

Tlf: +45 44 201 100 Tlf: +47 67 526 100

Deutschland Nederland

BioNTech Manufacturing GmbH Pfizer BV

Tel: +49 6131 90840 Tel: +31 (0)10 406 43 01

Eesti Österreich

Pfizer Luxembourg SARL Eesti filiaal Pfizer Corporation Austria Ges.m.b.H

Tel: +372 666 7500 Tel: +43 (0)1 521 15-0

Ελλάδα Polska

Pfizer Ελλάς A.E. Pfizer Polska Sp. z o.o.

Τηλ.: +30 210 6785 800 Tel.: +48 22 335 61 00

España Portugal

Pfizer, S.L. Laboratórios Pfizer, Lda.

Tel: +34914909900 Tel: +351 21 423 5500

France România

Pfizer Pfizer Romania S.R.L

Tél +33 1 58 07 34 40 Tel: +40 (0) 21 207 28 00

Hrvatska Slovenija

Pfizer Croatia d.o.o. Pfizer Luxembourg SARL

Tel: +385 1 3908 777 Pfizer, podružnica za svetovanje s področja farmacevtske dejavnosti, Ljubljana

Tel.: +386 (0) 1 52 11 400

Ireland Slovenská republika

Pfizer Healthcare Ireland Pfizer Luxembourg SARL,

Tel: 1800 633 363 (toll free) organizačná zložka

+44 (0)1304 616161 Tel: +421 2 3355 5500

Ísland Suomi/Finland

Icepharma hf Pfizer Oy

Simi: +354 540 8000 Puh/Tel: +358 (0)9 430 040

Italia Sverige

Pfizer S.r.l. Pfizer AB

Tel: +39 06 33 18 21 Tel: +46 (0)8 550 520 00

Κύπρος United Kingdom (Northern Ireland)

Pfizer Ελλάς Α.Ε. (Cyprus Branch) Pfizer Limited

Tηλ: +357 22 817690 Tel: +44 (0) 1304 616161

Latvija

Pfizer Luxembourg SARL filiāle Latvijā

Tel.: +371 670 35 775

This leaflet was last revised in {MM/YYYY}

This medicine has been given ‘conditional approval’. This means that there is more evidence to come about this medicine. The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.

Scan the code with a mobile device to get the package leaflet in different languages.

URL: www.comirnatyglobal.com

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.

This package leaflet is available in all EU/EEA languages on the European Medicines Agency website.

------------------------------------------------------------------------------------------------------------------------

The following information is intended for healthcare professionals only:

Administer Comirnaty intramuscularly after dilution as a primary course of 2 doses (0.3 mL each)

3 weeks apart.

A third dose may be given at least 28 days after the second dose to individuals who are severely immunocompromised.

A booster dose of Comirnaty should be given as early as 3 months after the primary vaccination course with Comirnaty in individuals 12 years of age and older.

Comirnaty may also be given as a booster dose to individuals 18 years of age and older who have received a primary vaccination course comprised of another mRNA vaccine or adenoviral vector vaccine.

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Handling instructions

Comirnaty should be prepared by a healthcare professional using aseptic technique to ensure the sterility of the prepared dispersion.

VIAL VERIFICATION OF COMIRNATY 30 MICROGRAMS/DOSE CONCENTRATE

FOR DISPERSION FOR INJECTION (12 YEARS AND OLDER)

• Verify that the vial has a purple plastic cap.

Purple cap • If the vial has a grey plastic cap, please make reference to the

Summary of Product Characteristics for Comirnaty 30 micrograms/dose dispersion for injection.

• If the vial has an orange plastic cap, please make reference to the

After Dilution Summary of Product Characteristics for Comirnaty 10 micrograms/dose concentrate for dispersion for injection.

THAWING PRIOR TO DILUTION OF COMIRNATY 30 MICROGRAMS/DOSE

CONCENTRATE FOR DISPERSION FOR INJECTION (12 YEARS AND OLDER)

• The multidose vial is stored frozen and must be thawed prior to dilution.

Frozen vials should be transferred to an environment of 2 °C to 8 °C to

No m ore than thaw; a 195 vial pack may take

2 hours at room 3 hours to thaw. Alternatively, frozen temperature vials may also be thawed for (up to 30 °C). 30 minutes at temperatures up to

30 °C for immediate use.

• The unopened vial can be stored for up to 1 month at 2 °C to 8 °C; not exceeding the printed expiry date (EXP). Within the 1-month shelf life at 2 °C to 8 °C, up to 12 hours may be used for transportation.

• Allow the thawed vial to come to room temperature. Prior to use, the unopened vial can be stored for up to

2 hours at temperatures up to 30 °C.

Thawed vials can be handled in room light conditions.

• Gently invert the vial 10 times prior to dilution. Do not shake.

• Prior to dilution, the thawed dispersion may contain white to off- white opaque amorphous particles.

DILUTION OF COMIRNATY 30 MICROGRAMS/DOSE CONCENTRATE FOR

DISPERSION FOR INJECTION (12 YEARS AND OLDER)

• The thawed vaccine must be diluted in its original vial with 1.8 mL of sodium chloride 9 mg/mL (0.9%) solution for injection, using a

21 gauge or narrower needle and aseptic techniques.

1.8 mL of sodium chloride 9 mg/mL (0.9%) solution for injection.

• Equalise vial pressure before removing the needle from the vial stopper by withdrawing 1.8 mL air into the empty diluent syringe.

Pull back plunger to 1.8 mL to remove air from vial.

• Gently invert the diluted dispersion

10 times. Do not shake.

• The diluted vaccine should present as an off-white dispersion with no particulates visible. Do not use the diluted vaccine if particulates or discolouration are present.

Gently × 10

• The diluted vials should be marked with the appropriate date and time.

• After dilution, store at 2 ºC to 30 ºC and use within 6 hours, including any transportation time.

• Do not freeze or shake the diluted dispersion. If refrigerated, allow the diluted dispersion to come to room temperature prior to use.

Discard Time

Record appropriate date and time.

Use within 6 hours after dilution.

PREPARATION OF INDIVIDUAL 0.3 mL DOSES OF COMIRNATY

30 MICROGRAMS/DOSE CONCENTRATE FOR DISPERSION FOR INJECTION (12 YEARS AND OLDER)

• After dilution, the vial contains

2.25 mL from which 6 doses of

0.3 mL can be extracted.

• Using aseptic technique, cleanse the vial stopper with a single-use antiseptic swab.

• Withdraw 0.3 mL of Comirnaty.

Low dead-volume syringes and/or needles should be used in order to extract 6 doses from a single vial.

The low dead-volume syringe and needle combination should have a dead volume of no more than

35 microlitres.

If standard syringes and needles are used, there may not be sufficient

0.3 mL diluted vaccine volume to extract a sixth dose from a single vial.

• Each dose must contain 0.3 mL of vaccine.

• If the amount of vaccine remaining in the vial cannot provide a full dose of

0.3 mL, discard the vial and any excess volume.

• Discard any unused vaccine within

6 hours after dilution.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.